Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia
Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia
This protocol will compare topical paromomycin to standard intralesional (IL) antimony (Sb)
 to placebo for L braziliensis in Bolivia.
Patients will be randomized between Paromomycin cream applied topically once daily for 20
 days (group 1--40 patients), pentamidine administered intralesionally at 120 ug/mm2 on days
 1, 3, 5 (group 2-20 patients), and cream vehicle applied topically once daily for 20 days
 (group 3-20 patients).

 After treatment, all patients will be followed for 1, 3, and 6 months.
Inclusion Criteria:

 -  Gender: Male or female

 -  Age: >12 yrs of age

 -  Presentation: 1-to-2 ulcerative lesions, each < 30 mm in largest diameter and with a
 total lesion area <900 mm2.

 -  Parasitology: Parasitological confirmation of the lesion will be made by visualization
 or culture of Leishmania from the biopsy or aspirate of the lesion.

 Exclusion Criteria:

 -  Previous treatment for leishmaniasis with Sb, pentamidine, amphotericin B,
 miltefosine, imidazoles, allopurinol in the last 3 months.

 -  Other diseases that would be likely in the PI's opinion to interact, either positively
 or negatively, with treatment.